• Explore /
  • Poster
  • / Peak study: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib in combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).

Peak study: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib in combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).

Abstract Poster

Authors

null

Michael C. Heinrich

Oregon Health & Science University Knight Cancer Institute, Portland, OR

Michael C. Heinrich , Neeta Somaiah , Jonathan C. Trent , Breelyn A. Wilky , Melissa Amber Burgess , Arun S. Singh , Steven Attia , Mark Agulnik , William D. Tap , Sebastian Bauer , Robin Lewis Jones , Cesar Serrano , Liangxing Zou , Kevin Moynihan , Julia Lawrence , Andrew J. Wagner

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers

Track

Esophageal and Gastric Cancer,Small Bowel Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05208047

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr TPS766)

DOI

10.1200/JCO.2024.42.3_suppl.TPS766

Abstract #

TPS766

Poster Bd #

N18

Abstract Disclosures

Similar Posters

First Author: William D. Tap

First Author: Hidekazu Hirano

First Author: William D. Tap

First Author: Suzanne George